Cardio3 Biosciences develops novel regenerative stem cell therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury.
Turnstone delivers press communication services addressing the Flemish media since Cardio3’s IPO in June 2013. We developed different projects to optimally approach the individual investors using online and offline communication tools. Turnstone organized the presentation of Cardio3 Biosciences at the Flemish Investor Meeting in cooperation with the Flemish Federation of Investors (VFB).
See www.c3bs.comOur services for this client